NYSE:BLCOMedical Equipment
Will Stronger 2026 Guidance And ARVO Data Shift Bausch + Lomb's (BLCO) Innovation-Led Growth Narrative?
In late April 2026, Bausch + Lomb raised its 2026 revenue guidance to US$5.42–US$5.52 billion and showcased more than 40 scientific data presentations across its eye health portfolio and pipeline at the ARVO 2026 meeting, while also advancing B‑vitamin–based AMD research and launching PreserVision AREDS3 in the U.S.
Together, the upgraded outlook and breadth of clinical and pipeline data underscored how Bausch + Lomb is tying science-led innovation directly to its commercial growth ambitions...